| Year |
Author |
Age |
Sex |
Comorbidities |
Infection type/location |
Antibiotics used |
Outcome |
| 2016 |
Rapsinski et al. [3] |
57 |
Male |
Gout, chronic alcohol use |
Infective endocarditis |
Piperacillin-tazobactam, ceftazidime (concern for cefepime related encephalopathy) |
Discharged to outpatient care (44-day hospital stay) |
| 2019 |
Gani et al. [4] |
63 |
Male |
Resistant HIV/AIDS |
Bacteremia |
Piperacillin-tazobactam (TMP-SMX for concurrent infection) |
Discharged to the nursing facility with 6-week antibiotic therapy |
| 2020 |
Goldberg et al. [5] |
72 |
Male |
End-stage renal disease, IgA nephropathy, AFib, heart failure with reduced EF, obesity, chronic venous stasis |
Bacteremia |
Ciprofloxacin |
Discharge to home with home health services and follow-up |
| 2021 |
Ezeokoli et al. [6] |
81 |
Male |
CAD, AFib, heart failure, CKD, DM2, CVA |
Bacteremia |
Cefepime, ciprofloxacin (prophylactic) |
Stable discharge to subacute rehabilitation |
| 2022 |
Vo et al. [2] |
83 |
Male |
DM2, hypertension, CAD, prostate cancer, COVID-19 pneumonia |
Urinary tract infection |
Ceftriaxone, cefepime |
Complete resolution of urinary symptoms, discharge at 15 day stay |
| 2023 |
This report |
70 |
Male |
BPH, COVID-19 infection, hypertension, CVA, CKD, encephalopathy with dementia |
CAUTI |
Cefepime, fosfomycin and ciprofloxacin (for concurrent infection) |
Stable discharge to skilled nursing facility |
